← Back to Lab Reference Library

Category: Liver & Kidney  |  Also known as: Symmetric Dimethylarginine, Serum SDMA  |  Sample: Serum (fasting not required; consistent conditions improve trend tracking)

1. What This Test Measures

SDMA (Symmetric Dimethylarginine) is a naturally occurring methylated arginine derivative produced when arginine residues in proteins are post-translationally methylated by protein arginine methyltransferase (PRMT) enzymes. As proteins are degraded during normal cellular turnover, methylated arginine residues are released as free SDMA into the bloodstream. Unlike standard arginine, methylated arginine residues cannot be recycled into new proteins and must be excreted as SDMA.

SDMA has three critical properties that make it the most sensitive early kidney biomarker available:

• Exclusive renal excretion: SDMA is cleared almost entirely by the kidneys through glomerular filtration, with essentially no tubular secretion or reabsorption and no significant non-renal clearance pathways. This makes rising serum SDMA almost exclusively reflective of declining glomerular filtration.
• Constant production independent of muscle mass: like cystatin C, SDMA production is driven by normal protein turnover throughout all tissues, not proportional to muscle mass. This makes it reliable across all body compositions without the sarcopenia and muscle mass confounders that limit creatinine.
• Superior sensitivity for early decline: SDMA rises detectably when GFR has declined by approximately 25%, compared to creatinine which does not rise detectably until 50 to 60% of GFR is lost. This window represents 1 to 2 years of additional lead time for intervention in many patients with progressive CKD.

SDMA is not only a kidney function marker; it is also a direct mediator of vascular disease through nitric oxide pathway disruption, making elevated SDMA simultaneously a kidney health and cardiovascular risk biomarker.

2. SDMA and the Nitric Oxide Connection

SDMA is a competitive inhibitor of all three isoforms of nitric oxide synthase (NOS), the enzyme family that produces nitric oxide (NO) from the substrate L-arginine. Nitric oxide is the primary endothelium-derived vasodilator, anti-platelet agent, and endothelial protectant in the cardiovascular system. When SDMA accumulates from kidney function decline, it directly impairs nitric oxide production through competitive inhibition at the NOS enzyme.

3. Standard Lab Reference Range

SDMA Level	Classification
Below 0.70 mcmol/L	Standard reference range upper limit (adult)
0.50 to 0.70 mcmol/L	Borderline functional medicine range; monitor closely
Above 0.70 mcmol/L	Elevated: reduced kidney filtration confirmed; evaluate full kidney panel

SDMA is not yet universally available on standard metabolic panels and may require specific ordering at reference laboratories. Its availability is expanding as clinical awareness of its utility grows. Some laboratories report in different units (nmol/L): 0.70 mcmol/L equals 700 nmol/L. The functional medicine optimal is below 0.50 mcmol/L (500 nmol/L).

4. Optimal Functional Medicine Range

SDMA Level	Functional Interpretation
Below 0.40 mcmol/L	Excellent: minimal nitric oxide pathway impairment; optimal kidney filtration
0.40 to 0.50 mcmol/L	Optimal: adequate kidney filtration; low endothelial risk
0.50 to 0.60 mcmol/L	Borderline: earliest kidney decline signal; address risk factors; check urine ACR; 6-month recheck
0.60 to 0.70 mcmol/L	Elevated (pre-threshold): meaningful decline; correlate with cystatin C; aggressive risk management
Above 0.70 mcmol/L	Elevated: significant filtration impairment; full kidney panel; nephrology consultation if progressing

5. Why SDMA Detects Kidney Disease Earlier Than Creatinine

The graphic below conceptually illustrates the detection timeline for each kidney marker as GFR progressively declines from 130 mL/min (young adult) to kidney failure:

GFR Level	SDMA	Cystatin C	Creatinine eGFR	Symptoms
120 to 130 mL/min (normal)	Below 0.50	Below 0.90	Above 90 (normal)	None
95 to 100 mL/min (25% loss)	0.50 to 0.60 (RISING)	0.90 to 1.00 (borderline)	Above 90 (still normal)	None
75 to 85 mL/min (40% loss)	0.60 to 0.70 (elevated)	1.00 to 1.15 (elevated)	75 to 85 (borderline)	Still none
52 to 60 mL/min (50 to 60% loss)	0.70 to 0.90	Above 1.15	Below 60 (NOW DETECTED)	Mild fatigue possible
30 to 45 mL/min (70% loss)	Above 0.90	Above 1.30	45 to 59 (Stage 3a/3b)	Symptoms emerging

The 25% GFR loss threshold at which SDMA becomes detectable represents an opportunity window of approximately 1 to 3 years before creatinine-based eGFR crosses the CKD diagnostic threshold of 60 mL/min. This is the intervention window where lifestyle changes, blood pressure control, and SGLT2 inhibitors have the greatest potential impact on slowing progression.

6. What Causes Elevated SDMA

• Reduced GFR from any cause: the primary and most clinically significant driver; CKD from diabetes, hypertension, glomerulonephritis, or other causes accumulates SDMA proportional to filtration loss; SDMA rises earlier than creatinine in all these conditions
• Aging: eGFR declines approximately 1 mL/min per year after age 40; SDMA rises progressively with age-related nephron loss; higher SDMA in older adults reflects genuine functional decline, not an artifact
• Acute kidney injury: SDMA rises rapidly with acute GFR reduction from sepsis, ischemia, contrast nephropathy, or other AKI causes; may rise within hours of the insult
• Hypertension: chronically elevated blood pressure reduces GFR through afferent arteriolar injury; SDMA rises in proportion to GFR loss
• Diabetes: hyperglycemia damages glomerular basement membrane and promotes hyperfiltration followed by progressive nephron loss; SDMA rises before creatinine in diabetic nephropathy
• NSAID use: reduces prostaglandin-mediated GFR support; chronic NSAID use produces SDMA elevation from reduced functional GFR
• Dehydration: acute GFR reduction from dehydration transiently raises SDMA alongside BUN; normalizes with hydration

7. How to Lower SDMA

8. The Complete Kidney Panel: Pattern Interpretation

SDMA is most clinically valuable when it rises before other kidney markers, revealing what creatinine and eGFR are missing:

SDMA	Creatinine eGFR	Cystatin C	Interpretation	Action
Below 0.50	Above 90	Below 0.90	No kidney concern; complete normal panel	Annual monitoring; manage metabolic risk
0.50 to 0.60	Above 90	0.90 to 1.00	Earliest detectable nephron loss; creatinine eGFR not yet affected	Aggressive risk factor management; 6-month recheck; urine ACR
0.60 to 0.70	75 to 89	1.00 to 1.10	Early CKD Stage 2; SDMA and CysC concordant; meaningful decline	Blood pressure, SGLT2i, nephrology awareness
Above 0.70	Below 60	Above 1.15	CKD Stage 3 or above; all markers agree; cardiovascular risk very high	Nephrology referral; intensified cardiovascular management
Above 0.60	Above 90	Below 0.90	Possible early SDMA rise in muscular patient or early nitric oxide impairment; recheck with urine ACR and blood pressure	Repeat in 3 months; check urine ACR

9. Related Lab Tests

10. When Testing Is Recommended

• Longevity and biological age panels: SDMA is one of the most sensitive markers of silent kidney aging and cardiovascular risk
• Diabetes and hypertension: annual SDMA testing enables earlier CKD detection than creatinine and eGFR alone
• Patients with cardiovascular disease: SDMA adds independent kidney-mediated cardiovascular risk assessment
• eGFR 75 to 90 mL/min: SDMA identifies whether this represents genuine early decline or body composition artifact
• Family history of CKD: SDMA enables proactive monitoring before conventional markers become abnormal
• Any patient on chronic NSAIDs: detect subclinical GFR impairment before creatinine rises
• Post-AKI monitoring: SDMA confirms recovery of filtration function after an acute kidney injury episode
• Hypertension management: SDMA provides early feedback on whether blood pressure control is protecting kidney filtration

11. Clinical Perspective

12. Frequently Asked Questions